{"id":"NCT05111145","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)","officialTitle":"A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-01-14","primaryCompletion":"2022-12-20","completion":"2022-12-20","firstPosted":"2021-11-08","resultsPosted":"2023-07-11","lastUpdate":"2023-07-11"},"enrollment":86,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in participants with CF who are 12 years of age or older.","primaryOutcome":{"measure":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 36","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":24,"countries":["Australia","Belgium","Canada","Czechia","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":86},"commonTop":["COVID-19","Infective pulmonary exacerbation of cystic fibrosis","Nasopharyngitis","Upper respiratory tract infection"]}}